In contrast with the studies above, Tsironis et al. [67] showed that patients with coronary disease exhibit reduced LDL-Lp-PLA2 mass and catalytic efficiency, suggesting a diminished ability to degrade pro-inflammatory phospholipids. The gene discussed is PLA2G7; the disease is coronary artery disorder.